Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 298 of 5804
-
Could a longer break between prostate cancer treatments boost quality of life?
Disease control Recruiting nowThis randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard way this medication is given. This study…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
AI picks who gets a second chance at targeted breast cancer therapy
Disease control Recruiting nowThe goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after they have progressed on the first CDK4/6 inhibitor. Patient…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New Scan-Guided radiation aims to cut side effects in recurrent prostate cancer
Disease control Recruiting nowPurpose: Prospective, single-site Phase II study testing whether PSMA-PET/MRI-guided, de-escalated salvage radiation reduces acute Grade ≥2 toxicity versus a 44% historical rate, while maintaining cancer control after prostatectomy.Population/Eligibility: Adult men ≥30 years with…
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New Triple-Drug attack targets tough leukemia
Disease control Recruiting nowThe purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compared to the usual chemotherapy treatment that people with this condition receive. …
Phase: PHASE2 • Sponsor: Justin Watts, MD • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New triple therapy offers hope for hard-to-treat nose and throat cancer
Disease control Not yet recruitingTo explore and evaluate the dose-limiting toxicity (DLT) profile of the fixed-dose combination of toripalimab, anlotinib, and chidamide in patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), and to determine the maximum tolerated dose (MTD) of chidamide, thereb…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New obesity drug HDM1005 takes on tirzepatide in head-to-head trial
Disease control Recruiting nowThis is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes. Eligible participants will be screened and randomized to different dose group of HDM1005 or the tirzep…
Phase: PHASE2 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for aggressive lymphoma: targeted combo trial launches
Disease control Not yet recruitingEvaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
MRI brain scan could prevent unnecessary stroke surgeries
Disease control Recruiting nowNarrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For l…
Phase: NA • Sponsor: Maastricht University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cocktail therapy aims to beat back stubborn leukemia
Disease control OngoingThe purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia
Phase: PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation boosts cancer drug in Tough-to-Treat myeloma
Disease control Recruiting nowTo learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for hard-to-treat breast cancer: experimental drug takes on standard therapy
Disease control Not yet recruitingThis is a prospective, multicenter, open-label, randomized, controlled Study. The purpose of this study is to evaluate the efficacy and safety of SHR-A1811 versus pyrotinib plus capecitabine in the treatment of trastuzumab primary-resistant HER2-positive advanced breast cancer.
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New triple therapy aims to shrink pancreatic tumors before surgery
Disease control Not yet recruitingThe goal of this clinical trial is to learn if surufatinib (VEGFR-TKI) plus toripalimab (PD-1 inhibitor) and mFOLFIRINOX (chemotherapy) works as neoadjuvant therapy for patients with high-risk or borderline resectable pancreatic cancer. It will also learn about the safety of the …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New shot takes aim at genetic high cholesterol
Disease control Recruiting nowHeterozygous Familial Hypercholesterolemia (HeFH) is an autosomal dominant disorder characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) and increased risk of atherosclerotic cardiovascular disease (ASCVD). This trial aims to evaluate the SYH2053 Injecti…
Phase: PHASE3 • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New triple-drug combo aims to keep advanced breast cancer in check
Disease control Not yet recruitingThis is a Prospective, Single-Arm, Observational, Real-World Study. The purpose of this study is to evaluate the safety and efficacy of pyrotinib combined with trastuzumab and pertuzumab for maintenance therapy in HER2-positive advanced breast cancer in the real-world setting.
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for seniors with aggressive lymphoma: Four-Drug cocktail aims to spare chemo
Disease control Recruiting nowThis is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen in older treatment-naive patients with large B-cell lymphoma.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for elderly AML patients: drug combo aims to control disease without harsh chemo
Disease control Not yet recruitingThis study is a single-arm, prospective, multi-center exploratory clinical trial. A total of 61 patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy will be enrolled. The Simon two-stage design will be adopted to control the t…
Phase: PHASE2 • Sponsor: First People's Hospital of Hangzhou • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Rechallenge therapy shows promise for Tough-to-Treat colorectal cancer
Disease control Not yet recruitingThis study is a phase II, open-label, multicenter clinical trial designed to evaluate two different treatment options for patients with metastatic colorectal cancer whose disease has progressed after standard therapies. The study compares a rechallenge treatment using irinotecan …
Phase: PHASE2 • Sponsor: Gruppo Oncologico Italia Meridionale • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can zapping the main tumor boost survival in advanced lung cancer?
Disease control Not yet recruitingFor patients with non-small cell lung cancer and more than five metastatic lesions (non-oligometastatic disease), does radical treatment of the primary lung lesion, in addition to pharmacotherapy, also provide benefits in terms of progression-free survival (PFS) and local control…
Phase: NA • Sponsor: Guizhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cord blood stem cells aim to repair hearts after attack
Disease control Not yet recruitingThis trial is a Phase II, multicenter clinical study. The purpose of this trial is to evaluate the safety and efficacy of MiSaver, a cellular therapy product, in patients who have experienced an acute myocardial infarction (AMI). Specifically, the study aims to assess the improve…
Phase: PHASE2 • Sponsor: HONYA Medical Co Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy aims to keep leukemia away after transplant
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Asciminib, a first in class allosteric inhibitor, as a add-on maintenance therapy can provides benefits and further prevents relapse in post allogenic hematopoietic stem-cell transplant (HSCT) of patients with Philadelphia chromosome…
Phase: PHASE2 • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC